Rotigaptide

Summary

Rotigaptide is a synthetic, investigational peptide that modifies cardiac gap junctions to improve intercellular electrical coupling. Developed as an anti‑arrhythmic agent, it is being studied for prevention of ventricular and atrial tachyarrhythmias and for protection against ischaemia‑reperfusion injury during myocardial infarction.

Mechanism of Action

Rotigaptide binds to connexin‑43 (Cx43) and connexin‑45 gap‑junction channels, increasing their conductance. It preserves phosphorylation of Cx43 at serine 297 and 368, counter‑acting ischaemia‑induced dephosphorylation that normally reduces channel opening. By stabilising the gap‑junction structure, the peptide enhances both electrical and metabolic coupling between cardiomyocytes, thereby reducing the substrate for re‑entrant arrhythmias.

What the Research Shows

Pre‑clinical work showed that rotigaptide enhances dye transfer and electrical conductance in rat, rabbit and human cardiomyocytes, and suppresses ventricular tachyarrhythmias induced by ischaemia, CaCl2 or aconitine. In dogs and rats it reduced infarct size after myocardial infarction. A porcine model demonstrated a 55 % reduction in infarct size when the peptide was given intravenously before reperfusion. Human translational studies reported protection of endothelial function after forearm ischaemia‑reperfusion, while separate vascular studies found no effect on basal tone or t‑PA release. Phase‑I trials in ~200 healthy volunteers confirmed intravenous safety, and larger patient trials are ongoing.

Reported Benefits

Animal studies consistently report anti‑arrhythmic activity, reduced infarct size, and protection from ischaemia‑reperfusion endothelial dysfunction. Early human safety data indicate a favourable tolerability profile with no drug‑related adverse events at therapeutic concentrations. The peptide’s novel mechanism—enhancing gap‑junction communication—offers a potential alternative to ion‑channel blockers, especially where conventional drugs are limited by pro‑arrhythmic risk.

Limitations of the Evidence

Clinical efficacy in patients with cardiac disease remains unproven; ongoing trials have not yet reported outcomes. Evidence for atrial fibrillation is limited and largely speculative. Human vascular studies showed no augmentation of vasodilatation or t‑PA release, suggesting the peptide’s effects may be confined to myocardial tissue. As an investigational agent, regulatory approval has not been granted, and long‑term safety data are lacking.

Safety Considerations

Phase‑I trials reported no drug‑related side effects in healthy volunteers receiving intravenous rotigaptide. Pre‑clinical toxicology showed no adverse effects even at plasma levels far exceeding therapeutic concentrations. Nonetheless, safety in patients with cardiac pathology has not been fully established, and routine clinical use is not approved. Caution is advised until larger efficacy and safety trials are completed.

How It Is Administered

Rotigaptide has been administered intravenously as a short bolus followed by continuous infusion in animal and early human studies. Subcutaneous delivery has also been explored in pre‑clinical work. The peptide is supplied as a sterile solution suitable for injection; no oral formulation is reported.

Routes of Administration

Goals & Uses

• Prevention of atrial fibrillationCardiovascular / AntiarrhythmicModerate
• Cardioprotection during ischemiaCardiovascular / CardioprotectionLow
• Post‑myocardial infarction ventricular arrhythmia reductionArrhythmiaLow
• Prevention of ventricular arrhythmiasCardiovascular / AntiarrhythmicModerate
• Atrial fibrillation managementArrhythmiaModerate

Contraindications

• Hypersensitivity to rotigaptide or peptide excipientsAllergicHigh

Adverse Effects

• Injection site reactionsLocalCommon
• Injection site painLocalCommonPain at the injection site
• HeadacheNeurologicUncommonPain in the head or upper neck
• HypotensionCardiovascularRareLow blood pressure
• NauseaGastrointestinalUncommonFeeling of sickness or urge to vomit

Drug Interactions

• Antiarrhythmic agentsModerate
• Concomitant anti‑arrhythmic drugsModerate

Population Constraints

• PregnancyReproductive SafetyRelative
• Severe hepatic or renal impairmentOrgan ImpairmentRelative
• Pediatric patientsAgeRelative
• PediatricsAgeRelative

Regulatory Status

• European UnionInvestigationalUnder clinical development
• United StatesInvestigationalInvestigational New Drug application filed
• United KingdomInvestigationalClinical trials ongoing

Rotigaptide has not received regulatory approval in any jurisdiction. Clinical development appears to have stalled after Phase I/II studies. It remains a research/investigational compound.

Evidence & Sources

• Improving cardiac gap junction communication as a new antiarrhythmic mechanism: the action of antiarrhythmic peptides
  Journal ArticleModerateDhein S, et al.2010-01-01T00:00:00.000000Z
• Recent advances in the pharmacological treatment of cardiac arrythmias
  Journal ArticleModerateGramley F, et al.2009-01-01T00:00:00.000000Z
• Pharmacological modulation of gap junction function with the novel compound rotigaptide: a promising new principle for prevention of arrhythmias
  Journal ArticleModerateKjølbye AL, et al.2007-01-01T00:00:00.000000Z
• Rotigaptide protects the myocardium and arterial vasculature from ischaemia reperfusion injury
  Journal ArticleModeratePedersen CM, et al.2016-01-01T00:00:00.000000Z
• The vascular effects of rotigaptide in vivo in man
  Journal ArticleModerateLang NN, et al.2008-01-01T00:00:00.000000Z
• Pharmacotherapy for atrial arrhythmias: present and future
  Journal ArticleModerateMazzini MJ, Monahan KM2008-01-01T00:00:00.000000Z

Frequently Asked Questions